Tempus Wealth Planning LLC Has $353,000 Holdings in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Tempus Wealth Planning LLC increased its stake in Sarepta Therapeutics, Inc. by 475.8% in Q2, holding 20,658 shares valued at approximately $353,000.
• Sarepta's stock has garnered mixed analyst ratings, with a consensus rating of "Hold" and a target price averaging $39.32, while Mizuho cut its price target to $14.00.
• The biotechnology company's revenue was up 68.4% year-over-year, reporting $611.09 million for the quarter, significantly exceeding estimates.

Tempus Wealth Planning LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 475.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,658 shares of the biotechnology company's stock after acquiring an additional 17,070 shares during the quarter. Tempus Wealth Planning LLC's holdings in Sarepta Therapeutics were worth $353,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $31,000. Ancora Advisors LLC raised its stake in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after buying an additional 300 shares during the period. Banque Transatlantique SA acquired a new position in Sarepta Therapeutics during the 1st quarter worth approximately $44,000. Finally, Pandora Wealth Inc. bought a new position in Sarepta Therapeutics in the first quarter worth approximately $45,000. 86.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on SRPT shares. Mizuho restated a "neutral" rating and set a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a report on Monday, July 21st. Guggenheim restated a "buy" rating and set a $22.00 price objective on shares of Sarepta Therapeutics in a report on Monday, September 15th. Scotiabank upgraded shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price objective for the company in a report on Friday, June 6th. Oppenheimer raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $30.00 to $37.00 in a research report on Tuesday, July 29th. Finally, Citigroup initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 22nd. They issued a "sell" rating on the stock. Nine investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and six have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $39.32.

Sarepta Therapeutics Stock Up 3.6%

Sarepta Therapeutics stock opened at $18.36 on Monday. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The firm's 50-day simple moving average is $17.64 and its 200 day simple moving average is $34.48. The stock has a market cap of $1.79 billion, a PE ratio of -21.10 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company's quarterly revenue was up 68.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.07 EPS. Research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.